An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.
REUTERS/Mike Segar/File Photo Acquire Licensing RightsNov 17 (Reuters) - Eli Lilly (LLY.N) on Friday extended the deadline for Point Biopharma Global (PNT.O) shareholders by about two weeks to Dec. 1 to sell their stock, due to low participation.
In October, Lilly agreed to acquire Point Biopharma in an all-cash deal valued at $1.4 billion to gain access to its experimental therapies that enable precise targeting of cancer.
Lilly, which has offered to buy Point Biopharma shares at $12.50 a piece and has all regulatory approvals for the deal, said the price will remain the same during the extended period.
The tender offer has been extended in order for the companies to satisfy the minimum tender condition.
Persons:
Eli Lilly, Mike Segar, Lilly, Mounjaro, Sriparna Roy, Shinjini
Organizations:
Company, REUTERS, Biopharma, Thomson
Locations:
Branchburg , New Jersey, Bengaluru